Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toward non-invasive CNS delivery: The emergence of brain shuttle peptides.

Advances in pharmacology (San Diego, Calif.)·2026

Same author

Brain delivery of proteins with shuttle peptides.

Advances in pharmacology (San Diego, Calif.)·2026

Same author

Preface.

Advances in pharmacology (San Diego, Calif.)·2026

Same author

Structural Insights Into Man<sub>9</sub> Recognition by the HIV Antibody 2G12 Revealed by Paramagnetic NMR.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Enhancing lectin recognition via precise fluorination: Man<sub>5</sub> glycomimetics for targeting DC-SIGN.

Bioorganic chemistry·2026

Same author

Correction to "Microfluidics-Based Ionic Catch and Release Oligosaccharide Synthesis (ICROS-Microflow) to Expedite Glycosylation Chemistry".

JACS Au·2025

Same journal

New drug discovery and development in India.

Drug news & perspectives·2013

Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010

Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010

Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010

Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010

Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Targeting DC-SIGN with carbohydrate multivalent systems.

Macarena Sánchez-Navarro¹, Javier Rojo

¹Instituto de Investigaciones Químicas, Universidad de Sevilla, Sevilla, Spain.

Drug News & Perspectives

|December 15, 2010

Summary

This summary is machine-generated.

Fucosylated compounds offer a targeted approach to DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin) activation, enhancing immune responses. This strategy shows promise for developing novel vaccines and inhibiting pathogen entry.

More Related Videos

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

Published on: April 18, 2016

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Experiment Videos

Last Updated: Jun 6, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

Published on: April 18, 2016

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Area of Science:

Immunology
Glycobiology
Vaccinology

Background:

Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a C-type lectin on immature dendritic cells crucial for adaptive immunity.
DC-SIGN recognizes pathogen-associated glycosylated proteins in a multivalent, calcium-dependent manner, influencing pathogen capture and immune responses.
Current strategies often use mannosylated compounds, but these lack selectivity for DC-SIGN, potentially interfering with other lectins like the mannose receptor.

Purpose of the Study:

To explore novel carbohydrate multivalent compounds for targeting DC-SIGN.
To investigate the potential of fucosylated compounds for specific DC-SIGN targeting, overcoming limitations of mannosylated systems.
To assess the utility of DC-SIGN targeting for inhibiting pathogen entry and developing new vaccines.

Main Methods:

Development and application of fucosylated carbohydrate multivalent compounds.
Evaluation of compound specificity for DC-SIGN versus other lectins (e.g., mannose receptor).
Assessment of immune response modulation and pathogen interaction via DC-SIGN targeting.

Main Results:

Fucosylated compounds demonstrate specific targeting of DC-SIGN, unlike mannosylated compounds.
This specificity avoids interference with other lectins, ensuring targeted immune modulation.
The approach shows potential for inhibiting pathogen entry and enhancing vaccine development.

Conclusions:

Fucosylated multivalent compounds represent a promising strategy for specifically targeting DC-SIGN.
This targeted approach can inhibit pathogen entry and contribute to the development of new vaccines against infections and cancer.
Further research is needed to fully elucidate the complex immune pathways involving DC-SIGN.